Product Description
Orinove is developing ORIN-1001 (Abraxane) as a treatment for Advanced Solid Tumors and Metastatic Breast Cancer. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT03950570)
Mechanisms of Action: IRE1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Orinove
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Esophageal Cancer|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Small Cell Lung Cancer|Triple Negative Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05154201 |
ORIN1001-C1 | P2 |
Completed |
Pancreatic Cancer|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Esophageal Cancer|Triple Negative Breast Cancer|Small Cell Lung Cancer|Prostate Cancer|Ovarian Cancer |
2023-01-30 |
69% |
2025-01-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03950570 |
ORIN1001-001 | P2 |
Completed |
Breast Cancer |
2023-01-30 |
40% |
2025-01-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|